| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/02/2009 | US20090170095 Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM |
| 07/02/2009 | US20090169700 Healthy Food Product |
| 07/02/2009 | US20090169640 Compositons for nasal administration of pharmaceuticals |
| 07/02/2009 | US20090169632 Sustained release composition and manufacturing method thereof |
| 07/02/2009 | US20090169630 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications |
| 07/02/2009 | US20090169625 Electrostatically Controlled Hydrogels |
| 07/02/2009 | US20090169615 Collagen Formulations for Improved Skin Care |
| 07/02/2009 | US20090169614 Methods of suppressing microglial activation and systemic inflammatory responses |
| 07/02/2009 | US20090169613 Targeting of tumor stem cells through selective silencing of boris expression |
| 07/02/2009 | US20090169612 Systemic Immune Activation Method Using Nucleic Acid-Lipid Complexes |
| 07/02/2009 | US20090169607 Pharmaceutical Compositions Comprising Cyclosporin |
| 07/02/2009 | US20090169598 Treatment of bacterial infections |
| 07/02/2009 | US20090169592 Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| 07/02/2009 | US20090169591 Medical articles for the treatment of tumors |
| 07/02/2009 | US20090169588 Compositions Containing Proteins for the Transfer/Recycling of Structurally Modified Lipids, and the Applications Thereof |
| 07/02/2009 | US20090169577 immunology; antibodies, immunoglobulins; chronic obstructive pulmonary disease |
| 07/02/2009 | US20090169574 Heteroclitic analogs and related methods |
| 07/02/2009 | US20090169569 APO-2L receptor agonist and CPT-11 synergism |
| 07/02/2009 | US20090169566 Bioactive compositions |
| 07/02/2009 | US20090169565 Neutrokine-alpha antibodies and methods of use thereof |
| 07/02/2009 | US20090169564 Stimulus Inducible Protein Kinase Complex and Methods of Use Therefor |
| 07/02/2009 | US20090169560 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof |
| 07/02/2009 | US20090169559 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 07/02/2009 | US20090169556 Vascular endothelial cell growth factor antagonists |
| 07/02/2009 | US20090169555 Administering the kinase to regulate mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis or an inflammatory response inclding developmental retardation, excessive apoptosis, cancer, restenosis and diabetic neuropathy; screening for drugs that stimulate or inhibit lipid phosphorylation |
| 07/02/2009 | US20090169554 Polypeptides of Leishmania Major and Polynucleotides Encoding Same and Vaccinal, Therapeutical and Diagnostic Applications Thereof |
| 07/02/2009 | US20090169552 NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5 |
| 07/02/2009 | US20090169551 Methods and compositions for activating or inhibiting vegf-d and vegf-c |
| 07/02/2009 | US20090169549 Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
| 07/02/2009 | US20090169543 Method for regulating immune function in primates using the Foxp3 protein |
| 07/02/2009 | US20090169542 Modulators of neuronal regeneration |
| 07/02/2009 | US20090169539 Pdgf fusion proteins incorporated into fibrin foams |
| 07/02/2009 | US20090169538 Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow |
| 07/02/2009 | US20090169537 Glutadon |
| 07/02/2009 | US20090169536 Polypeptide Having Phytase Activity and Nucleotide Sequence Encoding the Same |
| 07/02/2009 | US20090169535 Treatment of epilepsy by expressing st3gal-iii |
| 07/02/2009 | US20090169534 Variant Forms of Urate Oxidase and Use Thereof |
| 07/02/2009 | US20090169527 Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
| 07/02/2009 | US20090169523 Hsc self-renewal |
| 07/02/2009 | US20090169520 Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation |
| 07/02/2009 | US20090169517 Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules |
| 07/02/2009 | US20090169511 Mucosal Bioadhesive SLow Release Carrier for Delivering Active Principles |
| 07/02/2009 | US20090169510 treating hepatitis by modulating NS3/NS4 protease comprising contacting a NS3/NS4 protease with a compound of the invention |
| 07/02/2009 | US20090169509 O-linked glycosylation of peptides |
| 07/02/2009 | US20090169508 Opioid and opioid-like compounds and uses thereof |
| 07/02/2009 | US20090169507 Purine nucleoside analogues for treating flaviviridae including hepatitis c |
| 07/02/2009 | US20090169506 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/02/2009 | US20090169505 Novel vaccines against multiple subtypes of influenza virus |
| 07/02/2009 | US20090169504 Compounds and Pharmaceutical compositions for the treatment of Viral infections |
| 07/02/2009 | US20090169503 Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| 07/02/2009 | US20090169498 Controlled Release Gels |
| 07/02/2009 | US20090169491 Peptides Having Activities of Insulin Like Growth Factor-1 and their Uses |
| 07/02/2009 | US20090169485 Gene therapy and pharmaceutical composition for prevention and treatment of lung cancer |
| 07/02/2009 | US20090169476 Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| 07/02/2009 | US20090169473 Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor |
| 07/02/2009 | DE19963612B4 Neue spannungsabhängige Kaliumkanäle aus der Kv4-Familie sowie deren Verwendung zur Entwicklung von Therapeutika New voltage-dependent potassium channels of the Kv4 family, as well as their use for the development of therapeutics |
| 07/02/2009 | CA2710680A1 Anti-c35 antibody combination therapies and methods |
| 07/02/2009 | CA2710646A1 Medicament for the treatment of cancer of the pancreas |
| 07/02/2009 | CA2710417A1 Glycosylated glycopeptide antibiotic derivatives |
| 07/02/2009 | CA2710116A1 Preparations with rosehip extracts, and method of producing rosehip extracts |
| 07/02/2009 | CA2710062A1 Solid lipid microcapsules containing growth hormone in the inner solid core |
| 07/02/2009 | CA2709927A1 Mutant forms of streptolysin o |
| 07/02/2009 | CA2709915A1 New polypeptides having affinity for her2 |
| 07/02/2009 | CA2709913A1 Method of stimulating the motility of the gastrointestinal system using ipamorelin |
| 07/02/2009 | CA2709884A1 Antimicrobial compounds |
| 07/02/2009 | CA2709662A1 A method of treating neurodegenerative diseases |
| 07/02/2009 | CA2709645A1 Sm-protein based secretion engineering |
| 07/02/2009 | CA2709644A1 Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects |
| 07/02/2009 | CA2709500A1 Type iii secretion system component protein pa1698 of pseudomonas aeruginosa |
| 07/02/2009 | CA2709337A1 Haemostasis- modulating compositions and uses therefor |
| 07/02/2009 | CA2708626A1 Recovery of hydrophobic peptides from oils |
| 07/02/2009 | CA2708566A1 Edible product having an immunostimulating effect |
| 07/02/2009 | CA2707403A1 N-pyrazole-2-pyridinecarboxamide derivative |
| 07/02/2009 | CA2707032A1 Stabilized factor ix formulations containing trehalose |
| 07/02/2009 | CA2706183A1 Cross-linked hydrogel containing an active substance |
| 07/01/2009 | EP2075582A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 07/01/2009 | EP2075346A2 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/01/2009 | EP2075335A2 Methods and compositions for inhibiting neoplastic cell growth |
| 07/01/2009 | EP2075334A1 EG-VEGF nucleic acids and polypeptides and methods of use |
| 07/01/2009 | EP2075255A1 Human FGF-23 gene and gene expression products |
| 07/01/2009 | EP2075254A1 Therapeutic use of a growth factor, NsG33 |
| 07/01/2009 | EP2075253A1 Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
| 07/01/2009 | EP2075008A2 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 07/01/2009 | EP2075004A1 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy |
| 07/01/2009 | EP2075002A2 Use of myoblasts in the manufacture of a medicament for treating stress urinary incontinence |
| 07/01/2009 | EP2074999A1 Use of rubescensine a and derivatives thereof in pharmacy |
| 07/01/2009 | EP2074994A1 Enhanced ocular neuroprotection/neurostimulation |
| 07/01/2009 | EP2074987A1 Liposome composition of colistin for intravenous, oral, and cutaneous therapeutic use, and process for its preparation |
| 07/01/2009 | EP2074142A1 Compounds for stimulating p-glycoprotein function and uses thereof |
| 07/01/2009 | EP2074141A1 Protease resistant insulin analogues |
| 07/01/2009 | EP2074140A2 Fibrillation-resistant insulin and insulin analogues |
| 07/01/2009 | EP2074138A1 Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor |
| 07/01/2009 | EP2074137A1 Compounds as aptamer-dimers and their uses in diagnosis and therapy |
| 07/01/2009 | EP2073898A1 Complement inhibition for improved nerve regeneration |
| 07/01/2009 | EP2073836A2 Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases |
| 07/01/2009 | EP2073835A1 Antimetastatic effect on human cell disorders |
| 07/01/2009 | EP2073834A2 Methods for administering long-lasting hypoglycemic agents |
| 07/01/2009 | EP2073833A2 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| 07/01/2009 | EP2073832A2 Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| 07/01/2009 | EP2073831A1 Use of modified cyclosporins |